CARDIOVASCULAR
Starting with the development of a unique cell-based system for the identification of compounds modulating cardiac rhythm, Fluofarma developed key capacities to support drug discovery in the field of cardiovascular diseases.
IN VITRO CARDIAC ACTIVITY RECORDING
| Inositol triphosphate receptor channel function |
H9C2 Cells | PF 3.21 |
| hERG channel | HEK 293 | CV 5.6 |
| hERG trafficking | HEK 293 | CV 5.10 |
| hNav1.5 channel | HEK 293 | CV 5.7 |
| hKir2.1 channel | HEK 293 | CV 5.8 |
| hKir2.1 trafficking | HEK 293 | CV 5.13 |
| hCav1.2 channel | HEK 293 | CV 5.9 |
| Cardiac Electrophysiology - Learn More | ||
CARDIOVASCULAR RISK ASSESSMENT
| NEW ! Human cardiomyocytes | Cor 4U® – iCell® | CV 5.14 |
| Cardiovascular Risk Assessment - Learn More | ||
A UNIQUE CARDIAC ARRHYTHMIA CELL-BASED ASSAY
> ES cells differentiated in atrial cardiomyocytes are functionally synced, spontaneously generating heart-beating cycles
> High-throughput monitoring of calcium bursts by FLIPR® Tetra, to identify compounds modulating cardiac rhythm
> A cell-based system suited for screening, drug profiling and cardiotoxicity studies
ADDITIONAL CAPABILITIES
Fluofarma
2, rue Robert Escarpit
33 600 Pessac, France
Telephone +33 540 003 060
Contact us
WORLDWIDE PRESENCE
